ApiFix’s Minimally Invasive Deformity Correction System for non-fusion treatment of adolescent idiopathic scoliosis will become OrthoPediatrics’ 35th surgical system after closing.
The MID-C removable device features motion-preserving capabilities to avoid permanently limiting the range of motion in scoliosis patients.
ApiFix’s entire team, including CEO Paul Mraz, has joined OrthoPediatrics.
Terms of the deal included 934,768 shares of OrthoPediatrics common stock and $2 million in cash paid at closing, as well as milestone payments and an earnout over a four-year period.
More articles on devices:
Physician group furloughs, layoffs, hours cut: economic responses to the pandemic
15 new COVID-19 cases linked to orthopedic practice in Alaska
Orthopedic surgeons among specialists called to treat COVID-19 patients in NYC
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.